Gino Santini Net Worth

The estimated Net Worth of Gino Santini is at least $3.63 Milhão dollars as of 2 October 2023. Mr. Santini owns over 23,092 units of Intercept Pharmaceuticals Inc stock worth over $1,918,221 and over the last 19 years he sold ICPT stock worth over $1,378,340. In addition, he makes $336,356 as Lead Independent Director at Intercept Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Santini ICPT stock SEC Form 4 insiders trading

Gino has made over 11 trades of the Intercept Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 23,092 units of ICPT stock worth $351,691 on 2 October 2023.

The largest trade he's ever made was exercising 35,795 units of Intercept Pharmaceuticals Inc stock on 3 August 2020 worth over $103,090. On average, Gino trades about 2,380 units every 91 days since 2005. As of 2 October 2023 he still owns at least 100,959 units of Intercept Pharmaceuticals Inc stock.

You can see the complete history of Mr. Santini stock trades at the bottom of the page.

Gino Santini biography

Gino Santini is Lead Independent Director of the Company. From 1983 to 2010, Mr. Santini held a variety of commercial, operational and leadership roles of increasing responsibility at Eli Lilly and Company, including Senior Vice President, Corporate Strategy and Business Development from 2007 to 2010, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. Operations from 1999 to 2004 and President of the Women’s Health Franchise from 1997 to 1999. Mr. Santini has been a director of AMAG Pharmaceuticals, Inc. since February 2012, Allena Pharmaceuticals, Inc. since February 2012 (but will not be standing for re-election as a director of Allena Pharmaceuticals, Inc. at its 2020 annual meeting of stockholders, as disclosed in its Annual Report on Form 10-K filed with the SEC on March 16, 2020), Horizon Pharma plc since March 2012 and Collegium Pharmaceutical, Inc. since July 2012. Mr. Santini also serves on the board of directors of a number of private companies. During the prior five years, Mr. Santini previously served as a director of Vitae Pharmaceuticals, Inc. Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

What is the salary of Gino Santini?

As the Lead Independent Director of Intercept Pharmaceuticals Inc, the total compensation of Gino Santini at Intercept Pharmaceuticals Inc is $336,356. There are 11 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.

How old is Gino Santini?

Gino Santini is 64, he's been the Lead Independent Director of Intercept Pharmaceuticals Inc since 2018. There are 1 older and 22 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.

What's Gino Santini's mailing address?

Gino's mailing address filed with the SEC is C/O COMPASS PATHWAYS PLC, 33 BROADWICK ST., LONDON, X0, W1FODQ.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, eFrancesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Complete history of Mr. Santini stock trades at AMAG Pharmaceuticals, Collegium Pharmaceutical Inc, Horizon Therapeutics Plc, Intercept Pharmaceuticals Inc, Lilly(Eli) & Co, Allena Pharmaceuticals Inc, eCOMPASS Pathways plc

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Pruzanski,
  President, Chief Executive Officer, Director
• Jerome Durso,
  Chief Operating Officer
• Ryan Sullivan,
  General Counsel, Secretary
• Richard Kim,
  President, U.S. Commercial & Strategic Marketing
• Sandip Kapadia,
  Chief Financial Officer, Treasurer
• Gail Cawkwell,
  Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
• Lisa Bright,
  President, International
• David Ford,
  Chief Human Resource Officer
• Dr. Mark Pruzanski M.D.,
  Founder, Advisor & Director
• Jerome B. Durso,
  Pres, CEO & Director
• Paolo Fundaro,
  Independent Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Daniel Welch,
  Independent Director
• Daniel Bradbury,
  Independent Director
• Luca Benatti,
  Independent Director
• Nancy Miller-Rich,
  Independent Director
• Keith Gottesdiener,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Jason Campagna,
  Chief Medical Officer
• Christian Weyer,
  Executive Vice President - Research & Development
• Linda M. Richardson,
  Exec. VP & Chief Commercial Officer
• Jared M. Freedberg J.D.,
  Gen. Counsel
• Lisa M. DeFrancesco,
  Sr. VP of Corp. Affairs & Investor Relations
• Rocco Venezia,
  Chief Accounting Officer & Treasurer
• Bryan Ball,
  Chief Quality Officer & Sr. VP of Operations
• Andrew Saik,
  Chief Financial Officer
• Barbara Gayle Duncan,
  Chief Financial Officer
• Rachel Mc Minn,
  Chief Strategy Officer
• David Shapiro,
  Chief Medical Officer
• Linda M Richardson,
  EVP & Chief Commercial Officer
• S.P.A. Genextra,
  
• M Michelle Berrey,
  President, R&D and CMO
• Daniel Paul Regan,
  Chief Commerical Officer
• Jonathan Silverstein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Lorenzo Tallarigo,
  Director
• Klaus R Dr Veitinger,
  Director
• Sanj K Patel,
  Director
• Luciano Adorini,
  Chief Scientific Officer
• Nicole Williams,
  Director
• Francesco Micheli,
  
• Bryan Ball,
  Chief Qual. Officer & SVP Ops.
• Rocco Venezia,
  Chief Accounting Officer
• Dagmar Rosa Bjorkeson,
  Director
• Lisa De Francesco,
  SVP, IR & Corp. Affairs
• Jared Freedberg,
  General Counsel